Akhu Therapeutics is working on new medicine for anxiety and depression to be effective, fast, and safe for users and the environment. Anxiety and depression are among the most common mental illnesses, and they are major contributors to suicide, disability, and susceptibility to serious illnesses like heart disease and diabetes. Unfortunately, current therapies for anxiety and depression are only modestly effective, work very slowly, do not work for millions of sufferers, and/or exhibit numerous adverse side effects.

With respect to the side effects of a drug, its mechanism of action is a crucial factor. The mechanism of action that Akhu chose is blockade of the melanocortin-5 receptor (MC5R). This action is fundamentally different than that of any anti-anxiety drugs or anxiolytics (e.g., benzodiazepines) or antidepressant drugs (e.g., SSRIs) to ever reach the market. 

Akhu Therapeutics - Better Medicine for Anxiety and Depression
Intelligence in the Development of Medicine for Anxiety and Depression

Anxiolytics and antidepressants act on biological signals that regulate many different functions in the brain and body. Such broad actions are responsible for the well-known and well-documented adverse side effects of the drugs in current use. In contrast, MC5R, influences few functions in the brain and body. Therefore, MC5R blockers are expected to have fewer and milder side effects.

Surveys by Akhu or others show that in addition to lack of effectiveness, slow onset, and harsh side effects, drug pricing is a major concern for those using antidepressants. Although our MC5R blockers are in early development, our lead compound is extremely potent, relative to anxiolytics and antidepressants. Such potency makes it possible that it might be taken in very small doses, which would keep manufacturing costs low. In that case, the overall cost could be lower than that of the typical branded antidepressant.

Another problem with anxiolytics and antidepressants is that they are chemicals that remain active outside the body. As a result, they end up in streams and animals living in or near streams. In contrast, our lead compound is a biodegradable peptide (i.e., small protein) that is unlikely to pollute the environment.

29 thoughts on “”

  1. The speed of this drug is extraordinary. Antidepressant effects appears as soon I tested the animals with our drug. Traditional antidepressants take weeks for that test. When drugs are the best option to treat other illnesses, they act quickly. We want to bring the world an antidepressant that is as fast acting as drugs for other diseases. Help us revolutionize antidepressants!

  2. All new ideas are welcomed as always. Staying away from meds I dont need makes me bolder. So looking forward to hearing about these ideas.

    1. I agree. Turns out too many anti-inflammatory meds equals big trouble. Thank God Dr. DRAKE knew exactly what to do. Nothing wrong with me!! Concern is valid and well taken. Eyebrows raised repeatedly.

  3. There is valuable information to be found at this website about mental illness. I trust it will be disseminated.

  4. I’m really enjoying the theme/design of your website. Do you ever run into any browser compatibility problems? A handful of my blog audience have complained about my site not operating correctly in Explorer but looks great in Firefox. Do you have any ideas to help fix this problem?

  5. My husband had problems with memory loss after taking Prozac for over 15 years. It’s time for something new and maybe something to bring his memory back too.

    1. What happened to your husband is unfortunate and not uncommon. We don’t have data on how our products might improve memory, but we’re developing them because the have the potential to beat everything on the market. Please spread the word.

  6. As a sufferer of depression and anxiety which is partially responsive to SSRIs, I was following nemifitide over five years ago and still confused about what happened to it.

    Do you know how long it will take you approximately to develop these melanocortin inhibitors?

    Denise

    1. Nemifitide was the closest thing to a cure. Our hope is that our MC5R blockers continue to work as well as nemifitide only faster. Two things drive medicines to market – funding and publicity. We are currently seeking the necessary funding to complete animal testing. We would begin human testing one year later. Please spread the word. We also invite you to sign up for email notifications through our blog.

Leave a Reply

Your email address will not be published. Required fields are marked *